Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Scribe Therapeutics Inc. (Nasdaq: SCTX) priced an upsized IPO of 8,580,000 shares at $15.00 per share, the top of its range. Gross proceeds are expected at $128.7 million. The underwriters received a 30-day option for up to 1,287,000 additional shares. Shares are set to begin trading July 24, 2026, and close July 27.
How this was made
The 30-second read
Why it matters
The disclosed IPO terms (price, share count, gross proceeds, and underwriter option) set expectations for dilution and cash runway, which can drive first-day and post-IPO trading behavior.
Market read
This is a primary IPO pricing update with concrete deal size and a near-term listing date, making it actionable for IPO and small-cap biotech positioning.
What to watch
Watch for how much of the proceeds are earmarked for pipeline milestones in the final prospectus, and whether underwriter option exercise expectations influence short-term positioning.
Background
Scribe Therapeutics is a clinical-stage biotech focused on purpose-built in vivo CRISPR technologies and is conducting an upsized IPO.
Ticker impact
Scribe Therapeutics priced an upsized IPO at $15.00 for 8,580,000 shares, with 30-day option for 1,287,000 more shares.
Likely initial volatility around first trading day as investors digest dilution and capital-raise size.
This is a primary capital-raise disclosure with concrete terms (price, share count, gross proceeds) and a defined trading start date (July 24, 2026).
Market effects
Adds another clinical-stage CRISPR biotech to the public markets, potentially affecting near-term sentiment toward in vivo gene-editing IPOs.
Limited, primarily US biotech IPO flow and small-cap growth risk appetite.
Low; the event is company-specific and not a cross-border regulatory or macro catalyst.
Counterpoint
High-end pricing can also reflect a need to clear the book, and first-day trading may fade if dilution is perceived as heavy versus near-term clinical catalysts.
Key entities
- companyScribe Therapeutics Inc.
Clinical-stage biotech that priced its upsized IPO at $15.00 per share.
- venueNasdaq Global Market
Expected listing venue where shares begin trading July 24, 2026 under symbol SCTX.
- deal_partiesUnderwriters (Leerink Partners, Goldman Sachs, Guggenheim Securities, Wells Fargo Securities)
Joint book-running managers for the IPO.
